All In Biotech

Drug Trial Radar · NCT03665207

Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients

Impact of Tight Blood Glucose Control Within Normal Fasting Ranges With Insulin Titration Prescribed by the Leuven Algorithm in Adult Critically Ill Patients

Last checked: Nov 20, 2026Latest source record: Jun 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 9,230 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

9,230

Actual

Start

Sep 18, 2018

Primary completion

Nov 30, 2022

Study completion Nov 2026

Sponsor

Lead sponsor
KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Universitaire Ziekenhuizen KU Leuven; Research Foundation Flanders
First posted
Sep 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Critically ill patients usually develop hyperglycemia, which is associated with an increased risk of morbidity and mortality. Controversy exists on whether targeting normal blood glucose concentrations with insulin therapy, referred to as tight blood glucose control (TGC) improves outcome of these patients, as compared to tolerating hyperglycemia. It remains unknown whether TGC, when applied with optimal tools to avoid hypoglycemia, is beneficial in a context of withholding early parenteral nutrition. The TGC-fast study hypothesizes that TGC is beneficial in adult critically ill patients not receiving early parenteral nutrition, as compared to tolerating hyperglycemia.

Conditions

  • Critical Illness
  • Hyperglycemia

Interventions

  • InsulinDrug

    When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of ICU dependencyTime frame: up to 1 year after randomization

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Intensive Care Medicine, University Hospital Ghent

    Ghent, Belgium

  • Department of Intensive Care Medicine, Jessa Hospital Hasselt

    Hasselt, Belgium

  • Department of Intensive Care Medicine, University Hospitals Leuven

    Leuven, Belgium

  • Medical Intensive Care Unit, University Hospitals Leuven

    Leuven, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.